This site is intended for health professionals only
Thursday 27 June 2019
Share |

Topic: Respiratory

June 6, 2019
In the Phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps with inadequate response to intranasal corticosteroids
Novartis has announced positive topline data from two Phase III, multicentre studies evaluating omalizumab (Xolair®) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard-of-care (intranasal corticosteroids). 
 
Omalizumab, an injectable biologic treatment designed to target and block immunoglobulin E (IgE), met both co-primary endpoints and key secondary endpoints across both POLYP 1 and POLYP 2 Phase III trials.
June 6, 2019
The risk of pneumonia was highest among those using strong opioids, such as oxycodone or fentanyl, but the risk was also increased among those using buprenorphine, tramadol or codeine
Opioid analgesics were associated with a 30% increase in the risk of pneumonia in persons with Alzheimer’s disease, a recent study from the University of Eastern Finland shows.
 
The risk was most pronounced in the first two months of use. This is the first study to investigate the association between opioids and pneumonia in this population. The results were published in the Journal of Alzheimer’s Disease.1
 
May 30, 2019
QUARTZ is the first completed study of the Phase III PLATINUM clinical development program which evaluates both QMF149 and QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate)
Novartis has announced the first study results from the Phase III PLATINUM clinical development program assessing the safety and efficacy of QMF149, an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate (IND - a long-acting beta agonist [LABA]) and mometasone furoate (MF - an anti-inflammatory (ICS)).
 
May 23, 2019
Inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate) was superior to the standard of care (long-acting beta-agonist/inhaled corticosteroid) in terms of lung function in a Phase II study
New Phase II data for Novartis's IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide and mometasone furoate, delivered with the dose-confirming Breezhaler® inhalation device, has been presented at the 2019 annual international congress of the American Thoracic Society (ATS).
 
January 23, 2019
Those aged 18-29 are the most likely to suffer an asthma attack and least likely to receive life-saving asthma care than any other age group, research has revealed.

Those aged 18-29 are the most likely to suffer an asthma attack and least likely to receive life-saving asthma care than any other age group, research has revealed.
 
Two-thirds (67%) of patients in this group are not receiving basic asthma care – higher than any other age group – a survey of more than 10,000 asthma patients by the charity Asthma UK revealed.
 
Patients in this age group are also twice as likely to receive emergency asthma care than patients aged over 60, the charity said.
 

July 10, 2018
In draft guidance published on 9 July NICE recommended that healthcare professionals prescribe antibiotics to people with COPD only when suffering from severe acute exacerbation.

Antibiotics should be restricted when used for chronic obstructive pulmonary disease (COPD), the National Institute for Health and Care and Excellence (NICE) has urged.
 

July 10, 2018
In draft guidance published on 9 July NICE recommended that healthcare professionals prescribe antibiotics to people with COPD only when suffering from severe acute exacerbation.

Antibiotics should be restricted when used for chronic obstructive pulmonary disease (COPD), the National Institute for Health and Care and Excellence (NICE) has urged.
 

May 8, 2018
Major study proposes an algorithm that should be used to determine innovative drug prices with ‘a maximum level of transparency’.

A major study published in Nature Reviews states that a global revolution in new cancer drug pricing must occur if the world is to cope with rapidly increasing instances of the disease.

 

April 20, 2018
<p>Once-daily single inhaler triple therapy superior to Relvar, Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life</p>

GlaxoSmithKline and Innoviva, Inc have announced the publication in the New England Journal of Medicine of the landmark IMPACT study, one of the biggest ever conducted in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbations.1
 

March 13, 2018
The Steering Group on Influenza Vaccination was convened in November 2017, representing key stakeholders in the field of influenza. It is composed of eight members led by two co-chairs, including patient group representatives, healthcare professionals and academics

The Steering Group on Influenza Vaccination has released their Manifesto calling for more action to increase seasonal influenza vaccination coverage rates in Europe to reduce the unacknowledged burden of this disease.

 

November 17, 2017
Trelegy Ellipta is the first once-daily single inhaler triple therapy to be approved in Europe

GlaxoSmithKline and Innoviva, Inc have announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.
 

September 18, 2017
The proposed brand name is Trelegy Ellipta

GlaxoSmithKline and Innoviva, Inc have  announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone furoate/ umeclidinium/vilanterol (FF/UMEC/VI) as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.

 

September 14, 2017
An NTM lung infection can be a chronic and progressive condition that targets patients who are already struggling with pre-existing lung conditions, such as COPD, previous TB or bronchiectasis

Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced top-line data from its Phase III CONVERT study.

July 20, 2017
Humanised IL-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment

Teva Pharmaceutical Industries Ltd has announced that the National Institute for Health and Care Excellence (NICE) in England has recommended Cinqaero® (reslizumab) in its Final Appraisal Determination (FAD).

May 11, 2017
Primary objective was to investigate whether reducing eosinophils with subcutaneous mepolizumab would decrease the frequency of moderate and severe exacerbations in COPD patients at high risk of exacerbations despite use of optimal standard of care therapy

GlaxoSmithKline has announced preliminary results of two pivotal Phase III studies evaluating the efficacy and safety of mepolizumab, an IL-5 antagonist monoclonal antibody, as an investigational add on treatment for adults who have chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.

September 30, 2016
Approval of hybrid high-dose fluticasone/salmeterol maintenance treatment for people living with severe asthma and COPD, delivered via the award-winning Spiromax® inhaler to help patient usability

Teva Pharmaceutical Industries Ltd has announced that it has received EU marketing authorisation for Aerivio Spiromax® (fluticasone/salmeterol 500/50)1 as a maintenance bronchodilator treatment for adult patients with severe asthma and chronic obstructive pulmonary disease (COPD).

 

September 21, 2016
Survey revealed that physicians’ understanding of patients’ priorities align with patients’ actual priorities at diagnosis

Results of a new global survey supported by Boehringer Ingelheim of over 120 patients with idiopathic pulmonary fibrosis (IPF) show 9 out of 10 patients were happy with the way their doctor informed them of their diagnosis.1

 

However, a group of patients in the survey revealed there was additional information that would have been helpful to receive at that time. These include information about support, treatment and the realities of living with IPF:1

 

September 12, 2016
Lung involvement, such as interstitial lung disease, is the leading cause of death among people with systemic sclerosis

Boehringer Ingelheim has announced that the European Commission (EC) and US Food and Drug Administration (FDA) have granted Orphan Drug Designation to nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).

 

August 4, 2016
Therapy to be made available for patients with previously treated advanced non-small lung cancer whose tumours express the PD-L1 biomarker

MSD has announced that the European Commission (EC) has granted marketing authorisation for its immunotherapy treatment Keytruda (pembrolizumab) as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express programmed death ligand-1 (PD-L1) and who have had at least one prior chemotherapy regimen.1

 

April 14, 2016
New first-in-class inhaled antibiotic for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with Cystic Fibrosis now available in Germany and Denmark

Raptor Pharmaceuticals Corp. announced that Quinsair (levofloxacin nebulizer solution) is now available in Germany and Denmark. Quinsair is the first inhaled fluoroquinolone approved in the European Union for the management of chronic pulmonary infections due to P. aeruginosa in adults with cystic fibrosis (CF).1,2 The product is administered twice-daily, stored at room temperature and has a short administration time.

 

February 29, 2016
To mark Rare Disease Day 2016, Boehringer Ingelheim UK launches two new initiatives to support people living with the rare and devastating lung disease idiopathic pulmonary fibrosis (IPF)

Inspiration magazine – collaboration between patients, patient groups and leading clinicians puts IPF in the spotlight and calls for greater awareness and understanding of this devastating condition.
• International survey provides unique insights into the emotional truths of living with IPF – worry and fear are the most common emotions experienced when diagnosed with IPF; patient support groups make people with IPF feel less isolated and provide access to important information.

 

November 24, 2015
Novel inhaler approved for adults with chronic obstructive pulmonary disease (COPD)
  • Combination of salmeterol and fluticasone, a long established and proven treatment for COPD1
  • Award-winning intuitive delivery device could improve patient treatment adherence and clinical outcomes
  • Adherence to inhaled medication is significantly associated with reduced risk of death and admission to hospital due to exacerbations in COPD2

 

November 12, 2015
Campaign uses social video to raise awareness for chronic obstructive pulmonary disease (COPD)

Teva Pharmaceutical Industries Ltd. announced the launch of the #Laugh4Lungs campaign. This social media campaign aims to use the power of laughter to promote global awareness of chronic obstructive pulmonary disease (COPD) and to raise money for three leading COPD charities across Europe, including: the British Lung Foundation (UK), Longfonds (Netherlands) and Fundación Lovexair (Spain). #Laugh4Lungs is being launched in recognition of World COPD Day, which takes place on 18 November 2015.

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine